Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases
3d agoen
From the article
Conditions : Neuromyelitis Optica Spectrum Disease (NMOSD); Ripertamab Interventions : Drug: Riptylimab Sponsors : Zhongming Qiu Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Diagnosed with Anti-NMDA Receptor Encephalitis: A Personal Health Update
Andrew Gallant (creator of ripgrep) shares his recent diagnosis of anti-NMDA receptor encephalitis, an autoimmune disorder causing brain inf
burntsushi.net·1mo ago
Senolytic treatment linked to oligodendrocyte dysfunction and demyelination in brain study
This scientific research article investigates the effects of senolytic treatment (dasatinib and quercetin combination) on the corpus callosu
pnas.org·1mo ago
MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group
doi.org·3d ago
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK·17y ago
ClinicalTrials.gov
clinicaltrials.gov·25d agoGlial cells in chronic inflammation: diversity, dysfunction and therapeutic targeting
doi.org·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.